Efficacy and Safety Analysis by Overall Anti-drug Antibody Result up to Week 30 in Patients with Rheumatoid Arthritis Treated with SB2 (an Infliximab Biosimilar) or Reference Infliximab in a Phase III Study Choe, J., Smolen, J., Keystone, E., Genovese, M., Lee, Y., Rho, Y., Therrien, F. J RHEUMATOL PUBL CO. 2017: 872

View details for Web of Science ID 000404641800071